Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody

INTRODUCTION: Overexpression of c-Met, or hepatocyte growth factor (HGF) receptor, is commonly observed in tumor biopsies and often associated with poor patient survival, which makes HGF/c-Met pathway an attractive molecular target for cancer therapy. A number of antibody-based therapeutic strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lei, Xie, Kun, Li, Hongwen, Wang, Ruiqin, Xu, Xiaoqing, Chen, Kaiming, Gu, Hua, Fang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495354/
https://www.ncbi.nlm.nih.gov/pubmed/32982167
http://dx.doi.org/10.2147/DDDT.S254117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495354/
https://www.ncbi.nlm.nih.gov/pubmed/32982167
http://dx.doi.org/10.2147/DDDT.S254117

Ejemplares similares